Phase 4
Completed N=60
Subcostal TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Donor Nephrectomy Patients: A Prospective Study
Source: ClinicalTrials.gov NCT02287623 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcomePrimary: Numerical Rating Scale — 5; 3 scores on a scale
Summary
The primary objective of this study is whether one local anesthetic, liposomal bupivacaine, provides improved pain control and decreased opioid use compared to bupivacaine when injected during a transversus abdominis plane block for donor nephrectomy patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Numerical Rating Scale |
5; 3 | — |
| SECONDARY Post Operative Opioid Use |
160; 230 | — |
| SECONDARY Number of Patients With Post Operative Nausea/Vomiting |
7; 15 | — |
| SECONDARY Post Operative Length of Stay |
67.7; 78.1 | — |
| SECONDARY Postoperative Opioid Use |
190; 240 | — |
Eligibility Criteria
Inclusion Criteria
- presenting for donor nephrectomy
Exclusion Criteria
- non english speaking
- chronic pain condition
- taking chronic opioids
Data sourced from ClinicalTrials.gov (NCT02287623). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.